68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.
Nucl Med Commun
; 39(10): 871-880, 2018 Oct.
Article
em En
| MEDLINE
| ID: mdl-30124601
ABSTRACT
Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oligopeptídeos
/
Neoplasias da Próstata
/
Imageamento por Ressonância Magnética
/
Ácido Edético
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article